We could not find any results for:
Make sure your spelling is correct or try broadening your search.
(Adds analyst comments on market in paragraphs five and eight.) By Jon Kamp Of DOW JONES NEWSWIRES Johnson & Johnson (JNJ) said Monday it plans to bolster its lineup of stroke-prevention...
(Adds analyst comment on deal value in seventh paragraph.) By Jon Kamp Of DOW JONES NEWSWIRES Johnson & Johnson (JNJ) said Monday it plans to bolster its lineup of stroke-prevention products...
(Adds details on deal and competitors throughout; updates share prices.) By Jon Kamp Of DOW JONES NEWSWIRES Johnson & Johnson (JNJ) said Monday it plans to bolster its lineup of...
PLYMOUTH, Minn., July 6, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV), a global endovascular device company, today announced that it has reached an agreement with the plaintiffs to settle the...
PLYMOUTH, Minn., June 21, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV), a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted...
Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: BULL & LIFSHITZ, LLP ANNOUNCES INVESTIGATION OF...
Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Ev3 Inc.(NASDAQ: EVVV) (referred to as...
Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of ev3 Inc...
NEW YORK, NY -- (Marketwire) -- 06/02/10 -- Deltron, Inc. (OTCBB: DTRO) announced their corporate update yesterday, giving guidance on both wholly owned subsidiaries Blu Vu Life Support...
Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of ev3 Inc. (“ev3" or the “Company”) (NASDAQ:EVVV), related...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions